← Back to Search

Other

Study group for Insulin Sensitivity (CGM-PEPTIDE Trial)

N/A
Waitlist Available
Research Sponsored by Pennington Biomedical Research Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This study will determine whether the ratio between 24h C-peptide urinary excretion rate and average 24h circulating glucose represent a good correlate of what is measured by the gold standard, i.e. M (glucose disposal rate) from a euglycemic-hyperinsulinemic clamp

Eligible Conditions
  • Insulin Sensitivity

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

1Treatment groups
Experimental Treatment
Group I: Study groupExperimental Treatment1 Intervention
Participants will be recruited among those whose insulin sensitivity has been previously measured by a high-dose euglycemic-hyperinsulinemic clamp at Pennington Biomedical during the last 5 years and indicated their wiliness to be re-contacted for future research
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
24h Continuous glucose monitoring and urinary C-peptide collection
2021
N/A
~20

Find a Location

Who is running the clinical trial?

Pennington Biomedical Research CenterLead Sponsor
307 Previous Clinical Trials
181,148 Total Patients Enrolled
6 Trials studying Insulin Sensitivity
125 Patients Enrolled for Insulin Sensitivity
~3 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top